173 related articles for article (PubMed ID: 35857807)
21. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Ito M; Tanaka T; Toita A; Uchiyama N; Kokubo H; Morishita N; Klein MG; Zou H; Murakami M; Kondo M; Sameshima T; Araki S; Endo S; Kawamoto T; Morin GB; Aparicio SA; Nakanishi A; Maezaki H; Imaeda Y
J Med Chem; 2018 Sep; 61(17):7710-7728. PubMed ID: 30067358
[TBL] [Abstract][Full Text] [Related]
22. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Popova T; Manié E; Boeva V; Battistella A; Goundiam O; Smith NK; Mueller CR; Raynal V; Mariani O; Sastre-Garau X; Stern MH
Cancer Res; 2016 Apr; 76(7):1882-91. PubMed ID: 26787835
[TBL] [Abstract][Full Text] [Related]
23. Structural and Functional Analysis of the Cdk13/Cyclin K Complex.
Greifenberg AK; Hönig D; Pilarova K; Düster R; Bartholomeeusen K; Bösken CA; Anand K; Blazek D; Geyer M
Cell Rep; 2016 Jan; 14(2):320-31. PubMed ID: 26748711
[TBL] [Abstract][Full Text] [Related]
24. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Ekumi KM; Paculova H; Lenasi T; Pospichalova V; Bösken CA; Rybarikova J; Bryja V; Geyer M; Blazek D; Barboric M
Nucleic Acids Res; 2015 Mar; 43(5):2575-89. PubMed ID: 25712099
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
Jiang B; Jiang J; Kaltheuner IH; Iniguez AB; Anand K; Ferguson FM; Ficarro SB; Seong BKA; Greifenberg AK; Dust S; Kwiatkowski NP; Marto JA; Stegmaier K; Zhang T; Geyer M; Gray NS
Eur J Med Chem; 2021 Oct; 221():113481. PubMed ID: 33945934
[TBL] [Abstract][Full Text] [Related]
26. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity.
Fan Z; Devlin JR; Hogg SJ; Doyle MA; Harrison PF; Todorovski I; Cluse LA; Knight DA; Sandow JJ; Gregory G; Fox A; Beilharz TH; Kwiatkowski N; Scott NE; Vidakovic AT; Kelly GP; Svejstrup JQ; Geyer M; Gray NS; Vervoort SJ; Johnstone RW
Sci Adv; 2020 May; 6(18):. PubMed ID: 32917631
[TBL] [Abstract][Full Text] [Related]
27. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
28. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Vrábel D; Svoboda M; Navrátil J; Kohoutek J
Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
[TBL] [Abstract][Full Text] [Related]
29. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1.
Bartkowiak B; Liu P; Phatnani HP; Fuda NJ; Cooper JJ; Price DH; Adelman K; Lis JT; Greenleaf AL
Genes Dev; 2010 Oct; 24(20):2303-16. PubMed ID: 20952539
[TBL] [Abstract][Full Text] [Related]
30. Role and therapeutic potential of CDK12 in human cancers.
Chilà R; Guffanti F; Damia G
Cancer Treat Rev; 2016 Nov; 50():83-88. PubMed ID: 27662623
[TBL] [Abstract][Full Text] [Related]
31.
Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I; Frankum JR; Konde A; Miller RE; Rehman FL; Brough R; Campbell J; Sims D; Rafiq R; Hooper S; Chen L; Kozarewa I; Assiotis I; Fenwick K; Natrajan R; Lord CJ; Ashworth A
Cancer Res; 2014 Jan; 74(1):287-97. PubMed ID: 24240700
[TBL] [Abstract][Full Text] [Related]
33. Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.
Liu Y; Hao M; Leggett AL; Gao Y; Ficarro SB; Che J; He Z; Olson CM; Marto JA; Kwiatkowski NP; Zhang T; Gray NS
J Med Chem; 2020 Jul; 63(13):6708-6726. PubMed ID: 32502343
[TBL] [Abstract][Full Text] [Related]
34. Computational studies to explore inhibitors against the cyclin-dependent kinase 12/13 enzyme: an
Ghosh A; Jha PC; Manhas A
J Biomol Struct Dyn; 2023 Oct; ():1-14. PubMed ID: 37817503
[TBL] [Abstract][Full Text] [Related]
35. Pan-Cancer Analysis of
Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
[TBL] [Abstract][Full Text] [Related]
36. Tubule-specific cyclin-dependent kinase 12 knockdown potentiates kidney injury through transcriptional elongation defects.
Zhang YL; Tang TT; Ni WJ; Li ZT; Jiang LY; Wang Y; Zhou X; Cao JY; Yin Q; Jiang W; Zhao YJ; Gan WH; Zhang AQ; Li ZL; Wen Y; Lv LL; Liu BC; Wang B
Int J Biol Sci; 2024; 20(5):1669-1687. PubMed ID: 38481813
[TBL] [Abstract][Full Text] [Related]
37. Lack of evidence for CDK12 as an ovarian cancer predisposing gene.
Eeckhoutte A; Saint-Ghislain M; Reverdy M; Raynal V; Baulande S; Bataillon G; Golmard L; Stoppa-Lyonnet D; Popova T; Houdayer C; Manié E; Stern MH
Fam Cancer; 2020 Jul; 19(3):203-209. PubMed ID: 32172432
[TBL] [Abstract][Full Text] [Related]
38. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM
J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720
[TBL] [Abstract][Full Text] [Related]
39. Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
Elliott A; Zhang J; Zhang Q; Swensen J; Martin D; Xiu J; Geynisman DM; Vaena D; Herzog TJ; Holloway RW; El-Deiry WS; Spetzler D; Heath E; Stafford P; Korn WM
J Mol Diagn; 2021 Dec; 23(12):1761-1773. PubMed ID: 34562615
[TBL] [Abstract][Full Text] [Related]
40. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
Li Y; Zhang H; Li Q; Zou P; Huang X; Wu C; Tan L
Cancer Lett; 2020 Dec; 495():12-21. PubMed ID: 32941949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]